enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Pazopanib - Wikipedia

   en.wikipedia.org/wiki/Pazopanib

   Pazopanib, sold under the brand name Votrient, is an anti-cancer medication marketed worldwide by Novartis. It is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis .

3. List of adverse effects of pazopanib - Wikipedia

   en.wikipedia.org/wiki/List_of_adverse_effects_of...

   Tumour pain †; Myelosuppression † [Note 3]; Underactive thyroid; Dehydration; Low level of phosphate in the blood; Dizziness; Lethargy; Paraesthesia; Peripheral sensory neuropathy

4. Category:Drugs developed by Novartis - Wikipedia

   en.wikipedia.org/wiki/Category:Drugs_developed...

   Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more

5. Novartis Q3 Earnings Beats Expectations On Strong Sales ... - AOL

   www.aol.com/novartis-q3-earnings-beats...

   On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the consensus of $12.76 billion. Volume contributed 12 percentage ...

6. Tyrosine kinase inhibitor - Wikipedia

   en.wikipedia.org/wiki/Tyrosine_kinase_inhibitor

   Crystal structure of the second generation Bcr-Abl tyrosine-kinase inhibitor nilotinib (red) in complex with an Abl kinase domain (blue). Nilotinib is used to treat chronic myelogenous leukemia (CML), a hematological malignancy.

7. Sunitinib - Wikipedia

   en.wikipedia.org/wiki/Sunitinib

   Sunitinib is approved for the treatment of metastatic renal cell carcinoma. Other therapeutic options in this setting are pazopanib (Votrient), sorafenib (Nexavar), temsirolimus (Torisel), interleukin-2 (Proleukin), everolimus (Afinitor), bevacizumab (Avastin), and aldesleukin. Renal cell carcinoma is generally resistant to chemotherapy or ...

8. VEGFR-2 inhibitor - Wikipedia

   en.wikipedia.org/wiki/VEGFR-2_inhibitor

   VEGFR-2 is a 210-230 kDa glycoprotein expressed in vascular endothelial cells and in hematopoietic stem cells and binds VEGF-A. [2] [4] VEGFR-2 is closely related to VEGFR-1 for they have common and specific ligands but VEGFR-2 is a highly active kinase while VEGFR1 is an impaired receptor tyrosine kinase.

9. Angiogenesis inhibitor - Wikipedia

   en.wikipedia.org/wiki/Angiogenesis_inhibitor

   An angiogenesis inhibitor is a substance that inhibits the growth of new blood vessels (angiogenesis).Some angiogenesis inhibitors are endogenous and a normal part of the body's control and others are obtained exogenously through pharmaceutical drugs or diet.